Who Is Valisure and What Do They Do?
Valisure LLC is an independent analytical pharmacy and pharmaceutical testing laboratory founded in 2015 and based in New Haven, Connecticut. Valisure operates as a pharmacy that purchases commercial pharmaceutical products, tests them for purity and safety before dispensing, and publishes its findings publicly. Valisure has become known for identifying pharmaceutical safety issues that had not been detected by standard FDA oversight mechanisms, including NDMA in ranitidine (2019), NDMA in metformin (2020), and benzene in sunscreens (2021). Valisure is funded through its pharmacy operations and does not accept pharmaceutical industry funding, making its research financially independent of the companies it tests.
What Valisure Found in 2019
In 2019, Valisure's laboratory routinely tested ranitidine products as part of its standard pharmaceutical quality testing protocol. Using liquid chromatography-mass spectrometry (LC-MS/MS) — a highly sensitive and specific analytical chemistry technique — Valisure detected NDMA in all ranitidine products tested, at levels up to 304,500 nanograms per tablet. To put this in context: the FDA's acceptable daily intake limit for NDMA from all sources is 96 nanograms. A single Zantac tablet at Valisure's highest detected level contained more than 3,172 times the daily NDMA limit. Valisure then tested whether the NDMA was a degradation product of the tablet itself (shelf degradation) or was produced during metabolism. By dissolving ranitidine in simulated gastric acid at 37°C (body temperature), Valisure found that NDMA generation increased dramatically under these conditions, indicating that additional NDMA is produced in the stomach after ingestion.
The Citizen Petition and FDA Response
In June 2019, Valisure submitted a Citizen Petition to the FDA (Docket No. FDA-2019-P-2396) formally requesting that the FDA recall all ranitidine products from the market. The petition included Valisure's analytical data, methodology, and scientific reasoning. The Citizen Petition process allows any member of the public, including companies, to petition the FDA to take regulatory action. The FDA is required to respond to Citizen Petitions but is not required to grant them. In this instance, the FDA confirmed the core finding — NDMA was present in ranitidine at concerning levels — and ultimately took the requested market withdrawal action in April 2020, approximately 10 months after the petition was filed.
Subsequent Validation of Valisure's Findings
Valisure's initial findings were scrutinized and contested by pharmaceutical industry defendants, who argued that Valisure's simulated gastric condition testing was not accurately representative of in vivo conditions. However, subsequent independent research — including studies from Stanford University and other academic institutions — confirmed that ranitidine metabolism in the human body generates NDMA at levels far exceeding safe limits. A 2020 Stanford study using a pharmacokinetic approach found NDMA levels in human urine exceeding 47,000 nanograms following a standard ranitidine dose — consistent with Valisure's findings and inconsistent with safe human use. While the exact magnitude of NDMA generation under specific physiological conditions continues to be researched, the fundamental finding — that ranitidine use results in substantial NDMA exposure in the human body — has been confirmed by multiple independent research groups.
Frequently Asked Questions
Related Pages
Zantac NDMA Contamination Explained
NDMA contamination in Zantac is not an external manufacturing defect — it is an inherent property of the ranitidine molecule itself. Ranitidine is chemically unstable and generates NDMA as a degradation product, and additional NDMA is produced inside the human body during ranitidine metabolism. This made Zantac fundamentally dangerous regardless of which manufacturer produced it.
Zantac Settlement Expectations — State Court Litigation 2026
Zantac state court litigation in 2026 is in an active but early phase compared to fully mature mass torts. Bellwether trials in Delaware will begin to establish settlement values for the broader case pool. Settlement ranges of $200,000 to $3,000,000 are estimated for qualifying claims, with strong Stage IV/wrongful death cases commanding the highest values. Do not expect quick settlements — state court mass torts typically take years.
Zantac Statute of Limitations — State-by-State 2026 Analysis
The statute of limitations for Zantac cancer claims varies by state, typically 2 to 3 years from the date of cancer diagnosis or from when the claimant knew or should have known of the Zantac-cancer connection (the discovery rule). The April 2020 FDA withdrawal is often cited as the constructive notice date. Claimants with diagnoses from 2022 onward and those who can show delayed discovery may still have timely claims in 2026.
Cancers Covered by Zantac Litigation
Six cancer types are the primary qualifying diagnoses in active Zantac state court litigation in 2026: bladder, stomach, colorectal, esophageal, breast, and prostate cancers. Bladder and gastrointestinal cancers have the most robust scientific and epidemiological support. Strength of causation evidence and state court acceptance varies by cancer type, and an attorney can evaluate your specific diagnosis.
Zantac and Bladder Cancer
Bladder cancer is the cancer most strongly and consistently linked to NDMA exposure from ranitidine. NDMA is excreted in urine, directly bathing the bladder epithelium in the carcinogen. Bladder cancer carries a high recurrence rate even after successful treatment, meaning lifetime surveillance and repeat procedures create substantial ongoing medical costs that factor significantly into claim values.
Zantac Federal MDL Dismissal — What Happened
The federal MDL in the Southern District of Florida was dismissed in November 2022 after Judge Robin Rosenberg excluded all of the plaintiffs' general causation experts under the Daubert standard. This ruling applies only to federal court. It does not bind state courts. Active Zantac litigation continues in Delaware and California state courts in 2026 under different evidentiary standards.
Zantac State Court Litigation — Delaware and California 2026
Following the closure of the federal MDL in November 2022, Zantac litigation has continued and grown in state courts. Delaware Superior Court is the most active venue, with thousands of consolidated cases proceeding under coordinated case management orders. California state courts have also produced favorable rulings for plaintiffs. State court proceedings are independent of the federal MDL and proceed on their own timelines in 2026.
Zantac Eligibility Requirements
To qualify for a Zantac cancer claim in 2026, you generally need: (1) at least 1 year of regular Zantac or ranitidine use; (2) a diagnosis of a qualifying cancer type; (3) a medically plausible timeline between use and diagnosis; and (4) a claim that falls within your state's statute of limitations. State court filings are active in Delaware and California.
Zantac Brand vs. Generic — All Manufacturers Are Liable
The NDMA problem is inherent to the ranitidine molecule, not to any specific manufacturer or formulation. Branded Zantac (Sanofi, and previously GSK and Pfizer), generic ranitidine from Boehringer Ingelheim and others, and all store-brand versions carry the same risk. All ranitidine manufacturers are named defendants in Zantac litigation.
FDA Zantac Market Withdrawal — April 2020
On April 1, 2020, the FDA formally requested that all ranitidine manufacturers withdraw their products from the U.S. market. This unprecedented action — covering both prescription and OTC products from all manufacturers — marked the FDA's conclusion that the NDMA problem in ranitidine was unfixable and that ranitidine products posed an unacceptable cancer risk for consumers.
Proving Zantac Use — How to Obtain Pharmacy Records
Pharmacy records are the single strongest form of evidence of long-term Zantac use for litigation purposes. Major pharmacy chains maintain prescription records and often OTC purchase histories for many years. Your attorney can assist in obtaining these records through HIPAA authorizations and subpoenas.
Zantac / Ranitidine (NDMA Cancer) Lawsuit
Ranitidine, sold under the brand name Zantac by Sanofi and previously by GSK, Pfizer, and Boehringer Ingelheim, was one of the most prescribed heartburn and acid reflux medications in history. In 2019, the independent pharmaceutical testing laboratory Valisure discovered that ranitidine is inherently unstable and produces NDMA — N-nitrosodimethylamine, a probable human carcinogen — at levels up to 304,500 nanograms per tablet. The FDA acceptable daily intake limit for NDMA is 96 nanograms. In April 2020, the FDA requested that all manufacturers withdraw ranitidine products from the U.S. market. Consumers who took Zantac regularly for a year or more and subsequently developed bladder, stomach, colorectal, breast, prostate, or esophageal cancer may have viable legal claims. A federal MDL in the Southern District of Florida was dismissed in November 2022 when Judge Robin Rosenberg excluded plaintiffs' general causation experts under Daubert, finding their methodologies unreliable. However, that ruling applies only to federal court and does not bind state courts. Litigation continues in Delaware Superior Court and California state courts in 2026, where different expert standards and case-specific evidence can support claims.
View full case overview